Anthropic launches Claude Science and internal drug discovery programs

Anthropic is piloting internal preclinical drug discovery efforts and launching a new product, Claude Science, to test how its AI tools perform in real-world bioscience workflows beyond coding and document summarization. This Anthropic Claude drug discovery platform move signals that AI companies are expanding into science tooling, not just code generation.

What happened

At a San Francisco event on June 30, 2026, Anthropic announced it will run its own preclinical drug-discovery programs focused on neglected and rare diseases. The company also launched Claude Science, described as an AI workbench for researchers and drugmakers to streamline research, analyze data, and manage complex computing workflows.

The preclinical programs will focus on work before human testing. Anthropic has not named specific diseases yet. According to Eric Kauderer-Abrams, Anthropic's head of life sciences, the effort is about testing their tools: "We believe in the power of tight feedback loops, and there's no substitute for having our own experiences alongside you all in the trenches trying to develop drugs." Jonah Cool, head of life sciences partnerships and deployment, said the company will pursue areas that normal drug development economics do not incentivize, such as rare diseases with clear biology but challenging economics.

Industry ties run deep. Executives from Genentech, Bristol Myers Squibb, and Novartis attended the event. Novartis CEO Vas Narasimhan joined Anthropic's board earlier this year. Anthropic also acquired the AI biotech startup Coefficient Bio, reportedly for about $400 million.

Why AI builders should care

For AI builders and product teams, this initiative is a real-world testbed for Claude's capabilities in a high-stakes domain. The company plans to use Claude for tasks like target identification, molecule design, and data analysis in early-stage drug development. Success or failure in these preclinical workflows will reveal gaps in current AI-assisted drug discovery tools and influence how AI is integrated into bioscience.

Claude Science is designed as a workflow tool for scientists, similar to how Claude Code serves programmers. Jonah Cool explained: "You can't advance a tool like Claude Science and think about preclinical work if we are not engaged in that in any way, shape, or form." This approach creates tight feedback loops between the AI vendor and its scientific users, accelerating product improvement.

Practical implications

If the program yields insights, Claude Science could sharpen Claude's performance in bioscience fields and inform future product directions for AI builders targeting biotech or pharma clients. Even if no drug candidate ever reaches market, the exercise will help Anthropic understand where AI adds value in preclinical workflows and where current tools fall short.

This experiment also models a new collaboration pattern: AI companies running internal programs in verticals they serve. For pharma companies, it signals that AI vendors are willing to take on risk and share the experience of early-stage drug development, potentially leading to more effective tools.

Caveats

It is not known whether any drug candidates from this program will ever reach market. Anthropic has not stated whether it would develop, license, or partner on any resulting drug candidates. The economics of rare and neglected diseases remain challenging regardless of AI tooling quality. Preclinical work is far from human testing, and most early-stage drug candidates fail. The program is explicitly framed as a test of Claude's capabilities, not a commitment to deliver new medicines.

FAQs

What is Claude Science and how is it used in drug discovery?

Claude Science is an AI workbench for scientific research designed to help scientists streamline research, analyze data, and manage complex computing workflows. It was announced alongside Anthropic's preclinical drug discovery programs to support bioscience teams in tasks like target identification and molecule design. MIT Technology Review and CNBC describe it as a tool for researchers and drugmakers.

Which diseases is Anthropic targeting with its preclinical drug discovery program?

Anthropic stated the programs will focus on neglected and rare diseases, but no specific diseases have been named yet. The company plans to pursue areas that normal drug development economics do not incentivize. Source.

What does preclinical drug discovery involve and how far is this from human testing?

Preclinical work occurs before human testing and includes in-lab experiments and animal studies to assess safety and efficacy. After preclinical work, clinical trials in people can take years. Anthropic has not indicated any timeline for moving to human trials. Source.

Who are Anthropic's industry partners and advisers in this initiative?

Key industry ties include Novartis CEO Vas Narasimhan joining Anthropic's board, and executives from Genentech, Bristol Myers Squibb, and Novartis attending the launch event. Anthropic also acquired the AI biotech startup Coefficient Bio for about $400 million. Source.